Cancer Patient Confronts Willis Over Treatment Access

Auckland woman Catherine Cook’s desperate fight for access to Keytruda, a targeted treatment for triple-negative breast cancer (TNBC), isn’t just a personal tragedy – it’s a stark symptom of a systemic failure in New Zealand’s pharmaceutical funding model. While Keytruda is standard care in over 40 countries for early-stage TNBC, New Zealand continues to restrict access, forcing patients to shoulder crippling financial burdens or face a grim prognosis. This case is rapidly becoming a focal point for wider discontent over Pharmac’s funding delays and the growing disparity in healthcare access between New Zealand and its peers.

Triple-negative breast cancer, affecting 10-15% of diagnoses, is particularly aggressive and difficult to treat. The lack of estrogen, progesterone, and HER2 receptors means standard hormone therapies are ineffective, leaving chemotherapy as the primary option. Keytruda, an immunotherapy drug, offers a targeted approach that has demonstrated significant benefits in improving outcomes for early-stage TNBC patients. However, Pharmac, New Zealand’s pharmaceutical management agency, has been slow to approve wider funding, citing budgetary constraints and a complex prioritization process. The agency’s assessment began in 2023, with the drug added to the Options for Investment List (OFI) in 2025, but no timeline for actual funding has been provided.

The situation is further complicated by Pharmac’s recent consideration of trimming the OFI – the very list Keytruda is on – to provide “clarity.” This move, while intended to manage expectations, has been widely criticized as a potential setback for patients awaiting access to crucial medications. The Breast Cancer Foundation and patient advocates argue that delaying access to effective treatments ultimately increases healthcare costs, as patients with advanced disease require more intensive and expensive care. The argument that early intervention saves money, as Cook herself pleaded to Finance Minister Willis, is gaining traction, but faces resistance within a constrained budget environment.

The Forward Look

The pressure on Pharmac and the government is mounting. Cook’s petition, with over 17,000 signatures, and her direct appeal to Finance Minister Willis, have brought the issue into the political spotlight. However, the lack of direct comment from both Willis and Pharmac Minister David Seymour is concerning. The next few months will be critical. Here’s what to watch:

• Pharmac’s OFI Review: The outcome of Pharmac’s review of the OFI will be a key indicator of its commitment to addressing the medicines crisis. A significant trimming of the list would signal a further delay in funding for Keytruda and other essential drugs.
• Political Pressure: Continued public and political pressure, particularly leading up to the next election, could force the government to prioritize increased funding for Pharmac. Expect further petitions and advocacy efforts.
• Pharmac’s Internal Ranking: While Pharmac has declined to reveal Keytruda’s ranking on the OFI, any leaks or official announcements regarding its prioritization will be closely scrutinized. The initial low-priority recommendation from the Cancer Treatments Advisory Committee in 2023 suggests a significant hurdle remains.
• Potential for Cross-Party Support: The issue transcends political lines. If opposition parties champion increased pharmaceutical funding, it could create a bipartisan consensus and accelerate the process.

Ultimately, Catherine Cook’s story is a call to action. It highlights the urgent need for a fundamental re-evaluation of New Zealand’s pharmaceutical funding model, ensuring that patients have timely access to life-saving treatments, regardless of their financial circumstances. The current system is not only failing patients but also potentially creating a two-tiered healthcare system where access is determined by wealth, a situation that demands immediate attention and decisive action.